Previously, we showed equivalent prevention of IPF-CM effects between long term (24 h; oral pharmacokinetic mimic) and short term (60 min; inhalation pharmacokinetic mimic) nintedanib exposure, including inhibition of αSMA and COL1A [13] that were increased as a result of IPF-CM exposure [7]. The gene discussed is ACTA1; the disease is idiopathic pulmonary fibrosis.